Vertex Reports Phase 2 Data for Trilaciclib in Hypertension

Vertex today announced Phase 2 results for Trilaciclib in patients with Hypertension. The study demonstrated that Trilaciclib demonstrates sustained long-term efficacy compared to standard of care or placebo. These results provide important insights into the treatment of Hypertension and support the continued development of Trilaciclib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Trilaciclib was consistent with previous observations, with no new safety signals identified.